Navigation Links
Aratana Therapeutics to Report Second Quarter 2013 Financial Results
Date:7/23/2013

KANSAS CITY, Kan. and BOSTON, July 23, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, will host a conference call and live audio webcast on Tuesday, August 13, 2013, at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2013, and to provide an update on its pet therapeutics development programs.

Interested participants and investors may access the conference call by dialing (800) 860-2442 (U.S.), (866) 605-3852 (Canada), or (412) 858-4600 (international). An audio webcast will be accessible via the Investors Relations section of the Aratana Therapeutics website aratana.investorroom.com.  

A replay of the call will be available for 90 days beginning at approximately 10:00 a.m. ET on August 13, 2013. Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10031855. The webcast replay will remain available in the Investors Relations section of the Aratana Therapeutics website for 90 days.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into regulatory-approved therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (Media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
2. Aratana Therapeutics Adds To Drug Development Team
3. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
6. Aratana Therapeutics Completes $15 Million Series B Financing
7. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
8. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
9. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
10. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
11. Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ -  Equicare Health Inc ., ... been recognized as one of the top 100 companies ... international listing that distinguishes the top digital health companies ... great step forward this year continually upgrading our product ... customer base and team," says Len Grenier , ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D Therapeutics, Inc., a ... administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will ... of T3D-959 in mild to moderate Alzheimer’s patients at CTAD 2016. Preliminary results ...
(Date:11/30/2016)... ... November 30, 2016 , ... Microbial genomics leader uBiome will ... Huffington, as part of the Thrive Global pop-up store. This stunning 5,000 square ... explore the microorganisms in their gut, collectively known as the microbiome. , The ...
Breaking Biology Technology:
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):